首页 / 院系成果 / 成果详情页

Effectiveness of dolutegravir-based vs boosted darunavir-based first-line 3-drug regimens in people with HIV with advanced disease: A trial emulation 期刊论文

编号：

532C4474FA064C95498DBAD5DBB38CD7
作者：

Gagliardini, Roberta^[1] Giacomelli, Andrea^[2] Mussini, Cristina^[3] Cole, Stephen R.^[4] Edwards, Jessie K.^[4] Pinnetti, Carmela^[1] Raimondi, Alessandro^[5] Antinori, Spinello^[2] Nozza, Silvia^[6] Mazzotta, Valentina^[1] Marchetti, Giulia Carla^[7] Lo Caputo, Sergio^[8] Tavelli, Alessandro^[9,10,11] Monforte, Antonella d''Arminio Antinori, Andrea^[1] CozziLepri, Alessandro
语种：

英文
期刊：

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES ISSN：1201-9712 2025 年 155 卷 ; JUN
疾病分类：

艾滋病
关键词：

ART-na & iuml ve Integrase inhibitors Antiretroviral therapy AIDS Trial emulation
摘要：

Background: No randomized comparisons exist between dolutegravir (DTG) and boosted-darunavir (DRV/b) for people initiating treatment with advanced HIV. Methods: Antiretroviral therapy (ART)-na & iuml;ve people with HIV (PWH) with CD4 < 200 cells/mm(3) or AIDS who started a first-line three-drug regimen with DTG or DRV/b were included. The primary outcome was a composite endpoint of newly diagnosed AIDS, serious non-AIDS events (SNAE), death, virological failure (VF), or discontinuation of the anchor drug due to failure or toxicity. A marginal structural Cox regression model was used to estimate the effect of starting DTG vs DRV/b-based regimens. Results: A total of 1323 advanced ART-na & iuml;ve PWH were included, 895 starting DTG and 428 DRV/b. The unweighted risks of the composite endpoint by 48 months were 21.1% (95% CI: 18.1; 24.1%) for DTG vs 37.9% (95% CI: 32.7; 43.2%) for DRV/b ( P < 0.001). First-line treatment with DTG showed a lower risk of experiencing the composite endpoint than DRV/b (wHR of DTG vs DRV/b 0.47, 95% CI: 0.35; 0.64, P < 0.001). Conclusion: Under the stated assumptions, this analysis indicates that in ART-na & iuml;ve PWH with advanced disease, ART initiation with DTG vs DRV/b-based regimens leads to a 50% reduction in the risk of AIDS/SNAE/death/VF/discontinuation. This observed difference is partly explained by discontinuation of the anchor drug. (c) 2025 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
推荐引用方式
GB/T 7714：

Gagliardini Roberta,Giacomelli Andrea,Mussini Cristina, et al. Effectiveness of dolutegravir-based vs boosted darunavir-based first-line 3-drug regimens in people with HIV with advanced disease: A trial emulation [J].INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES,2025,155.
APA：

Gagliardini Roberta,Giacomelli Andrea,Mussini Cristina,Cole Stephen R.,&Cozzi-Lepri Alessandro.(2025).Effectiveness of dolutegravir-based vs boosted darunavir-based first-line 3-drug regimens in people with HIV with advanced disease: A trial emulation .INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES,155.
MLA：

Gagliardini Roberta, et al. "Effectiveness of dolutegravir-based vs boosted darunavir-based first-line 3-drug regimens in people with HIV with advanced disease: A trial emulation" .INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES 155(2025).
数据来源自科睿唯安Web of Science核心合集
入库时间：

2025/5/14 12:22:14
更新时间：

2025/5/14 12:22:14

浏览次数：12  下载次数：0

分享到：

浏览次数：12

下载次数：0

打印次数：0